207_Combined course Presentations

Role of PCI in ED-SCLC: EORTC 22993 trial

 N.B. response to chemotherapy (4-6 cycles) mandatory to enter this study

Survival benefit = 13.8% @1 year 27.1% vs 13.3%

 Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival

Slotman B. et al. NEJM 2007;357